Effect of NIC 002-induced antibodies on the pharmacokinetics of nicotine during cigarette smoking.
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2011
At a glance
- Drugs NIC 002 (Primary)
- Indications Smoking withdrawal; Substance-related disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Cytos Biotechnology
- 18 Aug 2011 Status changed from not yet recruiting to suspended.
- 05 Nov 2010 New trial record